ClinicalTrials.gg
RecruitingNCT07010432RAMBOUpdated Sep 10, 2026

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

A Phase 1 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Recruiting at 1 site in Denmark. Open to female participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Planned enrollment
19th of 36
144 · median 154
Started
2025
with 5 others
Phase 1
19 of 36
5 open now
Primary completion
2028-05
later than 11 of 14 live
Registered
22nd of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 19th largest by planned enrollment, is one of 6 that started in 2025, is one of 19 in phase 1, reaches primary completion later than 11 of the 14 other live ones, and was the 22nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 50 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide) or placebo. Which treatment participants get is decided by chance. Semaglutide is already approved for the treatment of overweight and obesity and can be prescribed by doctors. Cagrilintide and CagriSema are new medications currently under development for weight management. The study will last for about 79 weeks.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female.
  • at screening (defined as minimum 12 months of amenorrhea, high levels of follicular stimulating hormone (FSH) 16 - 130 international units per liter (IU/L), and low levels of anti-müllerian hormone (AMH) and inhibin B).
  • Age 50-70 years (both inclusive) at the time of signing the .
  • (BMI) greater than or equal to >= 30.0 kilograms per square meter (kg/m\^2).

Exclusion criteria

Exclusion criteria

  • Previous or current bone disease (e.g., osteoporosis, Paget's disease of bone, or bone cancer).
  • Presence of disease affecting bone metabolism (e.g., diabetes mellitus, hyperparathyroidism, hyper or hypothyroidism, chronic kidney disease, celiac disease, or inflammatory diseases (e.g., psoriatic arthritis or ankylosing spondylitis)).
  • Treatment with any medication affecting bone metabolism within 6 months prior to screening as judged by the investigator (e.g., anti-resorptive medication, anabolic medication, systemic hormone replacement therapy (HRT), or systemic ).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Cagrilintide

    Participants will receive once-weekly subcutaneous (s.c) injections of cagrilintide or placebo at stepwise doses every 4 weeks in a 16-week dose escalation period until target dose is achieved and maintained for 52 weeks as adjunct to a reduced calorie diet.

    Drug: Cagrilintide · Drug: Placebo cagrilintide

  • Experimental
    Semaglutide

    Participants will receive once-weekly s.c injections of semaglutide or placebo at stepwise doses every 4 weeks in a 16 week dose escalation period until target dose is achieved and maintained for 52 weeks as adjunct to a reduced calorie diet.

    Drug: Semaglutide · Drug: Placebo semaglutide

  • Experimental
    CagriSema

    Participants will receive once-weekly s.c injections of CagriSema (cagrilintide and semaglutide) or placebo at stepwise doses every 4 weeks in a 16 week dose escalation period until target dose is achieved and maintained for 52 weeks as adjunct to a reduced calorie diet.

    Drug: Cagrilintide · Drug: Semaglutide · Drug: Placebo cagrilintide · Drug: Placebo semaglutide

  • Placebo comparator
    Placebo

    Participants will receive once-weekly s.c injection of placebo matched to semaglutide and cagrilintide for 68 weeks.

    Drug: Placebo cagrilintide · Drug: Placebo semaglutide

Interventions

  • Participants will receive once-weekly cagrilintide subcutaneously.

  • Participants will receive once-weekly semaglutide subcutaneously.

  • DrugPlacebo cagrilintide

    Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.

  • DrugPlacebo semaglutide

    Participants will receive once-weekly placebo matched to semaglutide subcutaneously.

06

What researchers measure

Primary outcomes

  1. Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT)

    Measured in percentage (%).

    Time frame: From baseline to end of treatment (week 68)

Secondary outcomes

  1. Relative changes in vBMD of the lumbar 1 (L1) - L4 vertebrae assessed by QCT

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  2. Relative changes in vBMD of the radius assessed by QCT

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  3. Relative changes in vBMD of the L1 - L4 vertebrae assessed by QCT

    Measured in %.

    Time frame: From baseline to week 20

  4. Relative changes in vBMD of the radius assessed by QCT

    Measured in %.

    Time frame: From baseline to week 20

  5. Relative change in the Ki (bone turnover) of the femoral neck assessed by fluoride - positron emission tomography (PET)

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  6. Relative change in the Ki (bone turnover) of the femoral neck assessed by fluoride - PET

    Measured in %.

    Time frame: From baseline to week 20

  7. Relative changes in C-terminal telopeptide of type I collagen (CTX-1) and procollagen type 1 N-terminal propeptide (P1NP)

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  8. Relative changes in CTX-1 and P1NP

    Measured in %.

    Time frame: From baseline to week 20

  9. Relative changes in cortical thickness and porosity assessed by photon-counting computed tomography (PCCT)

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  10. Relative changes in trabecular thickness assessed by PCCT

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  11. Relative changes in number and separation of the femoral neck assessed by PCCT

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  12. Relative changes in L1-L2 vertebrae assessed by PCCT

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

  13. Relative changes in radius assessed by PCCT

    Measured in %.

    Time frame: From baseline to end of treatment (week 68)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 34 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 8, 2025
StartActual
Jun 12, 2025
Primary completionEst.
May 3, 2028
CompletionEst.
May 3, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07010432
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jun 12, 2025
Primary completion
May 3, 2028 (estimated)
Completion
May 3, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion